For submitting your details. We will call you as per the time given by you.
We are sorry. You have exceeded the number of requests permitted. This is in the interest of our investors. Please feel free to call us at toll free number for further queries.
The information and data contained in this Website do not constitute distribution, an offer to buy or sell or solicitation of an offer to buy or sell any Schemes/Units of Aditya Birla Sun Life Mutual Fund (ABSLMF), securities or financial instruments in any jurisdiction in which such distribution, sale or offer is not authorised. In particular, the information herein is not for distribution and does not constitute an offer to buy or sell or the solicitation of any offer to buy or sell any securities or financial instruments in the United States of America ("US") and Canada to or for the benefit of United States persons (being persons resident in the US, corporations, partnerships or other entities created or organised in or under the laws of the US or any person falling within the definition of the term "US Person" under the US Securities Act of 1933, as amended) and persons of Canada.
By entering this Website or accessing any data contained in this Website, I/We hereby confirm that I/We am/are not a U.S. person, within the definition of the term 'US Person' under the US Securities laws/resident of Canada. I/We hereby confirm that I/We are not giving a false confirmation and/or disguising my/our country of residence. I/We confirm that Aditya Birla Sun Life Mutual Fund / Aditya Birla Sun Life AMC Limited (ABSLAMC) is relying upon this confirmation and in no event shall the directors, officers, employees, trustees, agents of ABSLAMC associate/group companies be liable for any direct, indirect, incidental or consequential damages arising out of false confirmation provided.
The investment objective of the scheme is to provide long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Total Experience : 14 years
Use this tool by entering any amount you would have invested to calculate how much it would be worth today.
Internal rate of return or annualized yield for a schedule of cash flows occurring at irregular intervals.
Internal Rate of return or annualized yield for a schedule of cash flows occurring at irregular intervals for respective benchmark index.
Healthcare is an important part of our living. Right from birth till the end of life, we depend on healthcare. The cutting-edge advancements in Health & Pharma industry are not only giving us a better life but also increasing life expectancy. Add to that, growing awareness & incomes which are spear-heading greater use of healthcare solutions. The manufacturing driven Indian Pharmaceutical companies are gaining ground in exports. India is the largest producer of Generic drugs in the world. A domestic and an export led demand of Pharma & Healthcare services draws attention to its imminent rise. The Indian Pharmaceutical Industry having grown almost 3 times, from USD 12.6bn2 in 2009 to USD 38bn3 in 2018, constitutes a network of over 3,000 pharma companies housing about 10,500 manufacturing facilities. The Indian health care industry which stood at USD 110bn in 20174, includes in its ambit a wide network of hospitals, labs and diagnostics, medical equipment and supplies, medical insurance and emerging segments such as wellness products, contract research and biotechnology services. The Indian pharmaceutical and health sector is expected to achieve double digit growth figures in the years to come. This fund aims to help investors take advantage of this emerging sector by investing in pharma and healthcare companies which are well diversified business models with an optimal business mix across all main geographies – India, US & Emerging Markets. This fund would focus on areas like pharmaceuticals and formulations, speciality chemicals, hospitals and diagnostics, wellness products and other ancillary healthcare segments.
(An Open-ended Scheme*)
*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.
*Second Income/Regular Income/Monthly Income is not assured and is subject to availability of distributable surplus. Dividend distribution in the form of regular income to individual investors is subject to dividend distribution tax (DDT) of 13.5188% which is deducted by the fund house. For individual nature of tax implications, investors are requested to consult their tax advisors before investing.
**The portfolio of the scheme is subject to changes within the provisions of the Scheme Information Document. Please refer to the Scheme Information Document for asset allocation, investment strategy, and risk factors.
+Investors should note that declaration of dividends is at the discretion of Trustees and subject to availability of distributable surplus and there is no guarantee or assurance on the frequency or quantum of dividends. The NAV of the scheme pursuant to a payout of the dividend would fall to the extent of the payout and statutory levy (if applicable). For individual nature of tax implications, investors are requested to consult their tax advisor before investing.